The company

Eurocine Vaccines has attracted internationally recognized experts to quest for the vaccines of tomorrow. Specialized in vaccine development, and with decades long experience, the highly qualified team has a proven record to manage all aspects of vaccine development including preclinical and clinical development, scalability into production, as well as business development and financing.

Today a publicly listed company situated close to the Karolinska Institutet, home of the Nobel Assembly, using its clinically validated technology Endocine™ to develop new vaccines.​


Subscription warrants TO 3 / Teckningsoptioner TO 3

Villkor för teckningsoptioner av serie TO 3 i sammandrag

Innehavare av teckningsoptioner av serie TO 3 har rätt att för varje teckningsoption av serie TO 3 teckna en (1) ny aktie i Eurocine Vaccines AB under nyttjandeperioden 1–12 juni 2020. Teckningskursen kommer att uppgå till 70 procent av den genomsnittliga volymvägda kursen för aktien enligt Spotlight Stock Markets officiella kursstatistik under en period om 10 handelsdagar som slutar 29 maj 2020. Eurocine Vaccines AB kommer att offentliggöra teckningskursen senast dagen innan den första dagen i nyttjandeperioden tillsammans med information om hur man går tillväga för att nyttja sina teckningsoptioner av serie TO 3 genom ett pressmeddelande. Med hänvisning till gällande lagstiftning får teckningskursen inte understiga aktiens kvotvärde vid tidpunkten för aktieteckning. Teckningsoptionerna är föremål för sedvanliga omräkningsvillkor.

Teckningsoptioner av serie TO 3 är upptagna till handel på Spotlight Stock Market med kortnamn ”EUCI TO 3” och ISIN-kod SE0013668258. Sista dag för handel i teckningsoptioner av serie TO 3 är den 10 juni 2020.

Här följer även en Teaser med information om Bolaget och optionsinlösen:

Och här nedan finns ett försättsblad samt anmälningssedel:

Please find below the subscription form in English:

Se nedan för fullständiga villkor för teckningsoptioner TO 3:



President, CEO and Board Director

Dr. Hans Arwidsson

Dr. Hans Arwidsson, President, CEO and Board Director, is an executive with broad cross-functional experience from the pharmaceutical industry, e.g. Astra and AstraZeneca. Arwidsson holds a M.Sc. and a Ph.D. in pharmaceutical sciences from Uppsala University as well as an Executive MBA from Stockholm School of Economics.

Director of CMC Development

Ms. Sandra Jeldes Granstrand

Sandra Jeldes Granstrand, Director of CMC Development, Chemistry Manufacturing and Control, graduated as Master of Engineering, specialized in Bio-Medical Technology. Previously Deputy Head of Laboratory and CMC at Newron.

Director of Preclinical Development

Dr. Karl Ljungberg

Dr. Karl Ljungberg has an extensive experience of immunology, virology and particularly vaccinology from Karolinska Institutet, University of North Carolina and Public Health Agency of Sweden. Dr. Ljungberg holds a M.Sc. in Molecular Biology from Stockholm University and a Ph.D. in Infectious Disease Control from Karolinska Institutet.


Chairman of the Board

Dr. Pierre A. Morgon

Pierre A. Morgon holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He has previously served at senior positions at e.g. ICI-Pharma, Synthelabo, Aventis Sanofi Pasteur, Yamanouchi Pharma, BMS, Drug Abuse Sciences, Schering-Plough and Bio Alliance Pharma. Today he is CEO of MRGN Advisors, Chairman of Virometix and Theradiag, Board Member of Vaccitech and Univercells, as well as Regional Partner of Merieux Develeppement.

Non-Executive Director of the Board

Mr. Jan Sandström​

Jan Sandström, Master of Pharmaceutical Sciences, has both an extensive experience from the pharmaceutical industry as Business Developer and Board Member including Astrazeneca, PledPharma and TikoMed.

Non-Executive Director of the Board

Mr. Pär Thuresson

Pär Thuresson is president and CEO of an Industry Group and is also serving as a non-executive Director in several other companies.

Non-Executive Director of the Board

Prof. Emanuele Montomoli

Emanuele Montomoli is the founder, principal owner and Chief Scientific Officer of VisMederi srl, a considerable owner in Eurocine Vaccines AB. VisMederi srl is a private company that participates in clinical studies, where vaccines against human infectious diseases are studied, together with other pharmaceutical companies. He is a professor of Public Health in the Department of Molecular Medicine at the University of Siena, Italy and holds both a bachelor’s degree and a master’s degree in Life Science from the same university.

Emanuele Montomoli is currently participating in two EU-funded projects that are developing new methods to evaluate vaccines and vaccine adjuvants. He is a board member of the ISIRV Society (International Society for Influenza and other respiratory viral diseases) and has published nearly 70 scientific articles and several chapters in scientific textbooks in the field.

President, CEO and Board Director

Dr. Hans Arwidsson

Please see Management above.

Stakeholders & Governance

Eurocine Vaccines (EUCI) is listed at Spotlight Stock Market. Among the major shareholders you may find board members, partners and employees along with over 4 000 other shareholders.

Legal advisor is Advokatfirman Lindahl.

Next financial report, Interim Report July 2020 – September 2020, will be released November 25th 2020.

The Annual Report for the fiscal year 2019/2020 is planned to be released November 25th 2020.

The Annual General Meeting will be held December 15th 2020.

List of Shareholders

Do you want to follow Eurocine Vaccines development?

Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.

Start your subscription here »